Merck Discontinues Late-Stage Trial for Cancer Combination Therapy

Keytruda and Anti-TIGIT Treatment Combination Halted

Merck (MRK) has discontinued a late-stage clinical trial evaluating the combination of its blockbuster immunotherapy Keytruda and an investigational anti-TIGIT therapy. The decision was made after a review of data from the trial showed that the combination did not meet its pre-specified endpoints.